Submission date
16/01/2009
Registration date
16/02/2009
Last edited
21/04/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Retrospectively registered
? Protocol not yet added
? SAP not yet added
Results added
? Raw data not yet added
Study completed

Plain English Summary

Not provided at time of registration and not expected to be available in the future

Study website

Contact information

Type

Scientific

Contact name

Prof Isabelle Desguerre

ORCID ID

Contact details

Groupe hospitalier Necker - Enfants Malades
149 rue de Sèvres
Paris Cedex 15
75743
France

Additional identifiers

EudraCT/CTIS number

2008-003856-32

IRAS number

ClinicalTrials.gov number

Protocol/serial number

CL3-90652-004

Study information

Scientific title

Assessment of the effect of perindopril orodispersible tablet at the dose of 0.150 mg/kg/day on muscular and myocardic functions in the early stage of Duchenne Muscular Dystrophy: a two-year, double-blind, randomised, placebo-controlled study

Acronym

Study hypothesis

Effect on peripheral muscular function.

Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

Study design

Double-blind randomised placebo-controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type

Treatment

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

Duchenne Muscular Dystrophy

Intervention

Perindopril orodispersible tablet 0.150 mg/kg/day versus placebo for two years.

Intervention type

Drug

Pharmaceutical study type(s)

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Perindopril

Primary outcome measure

Six-minute walking distance, evaluated each 6 months

Secondary outcome measures

1. Other muscular tests
2. Echocardiography
3. Respiratory function assessment

Evaluated at inclusion visit and end-of-study visit

Overall study start date

01/02/2009

Overall study end date

30/09/2012

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

Children, less than 7 years old with Duchenne Muscular Dystrophy and able to complete a 6-minute walk test

Participant type(s)

Patient

Age group

Child

Upper age limit

7 Years

Sex

Male

Target number of participants

40

Total final enrolment

40

Participant exclusion criteria

1. Long term treatment with corticoids
2. Treatment with ACE inhibitors or AT1 antagonists

Recruitment start date

01/02/2009

Recruitment end date

30/09/2012

Locations

Countries of recruitment

France

Study participating centre

Groupe hospitalier Necker - Enfants Malades
Paris Cedex 15
75743
France

Sponsor information

Organisation

Institut de Recherches Internationales Servier (France)

Sponsor details

50 rue Carnot
Suresnes
92284
France

Sponsor type

Industry

Website

http://www.servier.com/

ROR

https://ror.org/034e7c066

Funders

Funder type

Industry

Funder name

Institut de Recherches Internationales Servier (France)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results No No
Basic results 21/04/2020 No No

Additional files

Editorial Notes

21/04/2020: The following changes were made to the trial record: 1. Added clinicaltrialsregister.eu link to basic results (scientific). 2. The total final enrollment was added. 23/11/2018: Link to basic results added.